| HOME >> BIOLOGY >> TECHNOLOGY |
NEW YORK and SAN DIEGO, May 18, 2011 /PRNewswire/ -- Ludwig Institute for Cancer Research LTD (LICR) and Polaris Group (Polaris) today announced the formation of a collaboration to expand development of Polaris' novel cancer drug, pegylated arginine deiminase (ADI-PEG 20). ADI-PEG 20 kills tumor cells by depletion of the amino acid arginine.
As part of the collaboration, LICR and Polaris will explore further the potential of ADI-PEG 20 as a cancer therapy and aim to identify other amino acid-degrading enzymes with anti-tumor activity. The collaboration builds on an existing relationship under which LICR and Polaris have studied ADI-PEG 20 in melanoma and are currently conducting a Phase 2 clinical trial in small cell lung cancer (SCLC) that was initiated in December 2010. LICR is the sponsor of the SCLC clinical trial, and LICR and Polaris are sharing expenses and resources to conduct this trial.
"We are delighted to have this agreement with Polaris," said Andrew Simpson, Ph.D., Scientific Director of LICR. "This collaboration builds on the work of Lloyd Old, M.D. of LICR and his seminal work on amino acid-degrading enzymes, including asparaginase and arginine deiminase, as anti-cancer treatments. We look forward to continuing our close working relationship with Polaris."
Bor-Wen Wu, Ph.D., Chief Executive Officer of Polaris, said, "This agreement is the fruit of many years of collaboration between LICR and Polaris, and is an opportunity to leverage the strengths of both organizations to attempt to bring ADI-PEG 20 to patients. In particular, I would like to thank Dr. Old for his vision, guidance and dedication to this project, and to his mentoring as we have moved ADI-PEG 20 from pre-clinical studies into human clinical trials."
Dr. Old commented: "The actions of antibodies and enzymes are remarkable for their high degree of specificity, and it is this property that makes them so attractive as potential anti-cancer agents
'/>"/>
| SOURCE Polaris Group Copyright©2010 PR Newswire. All rights reserved |
Related biology technology :
1. Polaris Group and The Ludwig Institute for Cancer Research Ltd Initiate Phase 2 Trial of Amino-Acid Degrading Enzyme, ADI-PEG 20, in Patients with Small Cell Lung Cancer
2. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
3. Larta Institute Receives Award for National Institutes of Health Commercialization Assistance Program at 2011 Acquisition, Grants, and Small Business Symposium
4. Van Andel Institute Earns Highest "Green Building" Award
5. LifeNet Health Breaks Ground on New Institute of Regenerative Medicine
6. The Wound Institute® to Feature Educational Forum on Dynamic Reciprocity During the Symposium on Advanced Wound Care and the Wound Healing Society Annual Meeting
7. MabVax Therapeutics Receives $1.8 Million in a Phase 2 Small Business Innovation Research Program Award From the National Cancer Institute
8. IBM and The Institute of Bioengineering and Nanotechnology Find Breakthrough for MRSA Treatment
9. Ontario Institute for Cancer Research Announces Investment in Microfluidics Technology for the Discovery of Anti-Cancer Drugs
10. Ontario Institute for Cancer Research Announces Enhancements to its Intellectual Property Development and Commercialization Program
11. Koch Institute for Integrative Cancer Research Dedicated Today
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |